Metabolic Disorders

Supporting Metabolic Disorders Research

Metabolic diseases, including diabetes, hypertension, and nonalcoholic fatty liver disease, have seen a significant increase globally over the past two decades.

In 2019, the prevalence of these conditions was notably high, with type 2 diabetes affecting approximately 5,283 per 100,000 people and nonalcoholic fatty liver disease affecting around 15,023 per 100,000 people. These diseases contribute substantially to global morbidity and mortality rates, highlighting the urgent need for effective research and interventions​¹. In response to this, pharmaceutical companies are investing heavily in the research and development of treatments for metabolic diseases. In 2020, the global expenditure on diabetes alone was estimated to be around $760 billion, a figure that underscores the substantial financial commitment to combating these widespread conditions​²​.

Sampled offers crucial support for metabolic disease research by providing services such as biobanking, genomic analysis, and biosample management. These services enable researchers to access high-quality samples and data, accelerating the discovery of new treatments and interventions for metabolic diseases. Sampled’s advanced analytical capabilities, including next-generation sequencing and proteomics, facilitate deeper insights into the genetic and molecular underpinnings of these disorders, ultimately contributing to more effective and personalized medical solutions.